Ruben A Mesa1, Alessandro M Vannucchi2, Adam Mead3, Miklos Egyed4, Anita Szoke5, Aleksandr Suvorov6, Janos Jakucs7, Andrew Perkins8, Ritam Prasad9, Jiri Mayer10, Judit Demeter11, Peter Ganly12, Jack W Singer13, Huafeng Zhou13, James P Dean13, Peter A Te Boekhorst14, Jyoti Nangalia15, Jean-Jacques Kiladjian16, Claire N Harrison17. 1. Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA. Electronic address: mesa.ruben@mayo.edu. 2. Center of Research and Innovation of Myeloproliferative Neoplasms, Department of Experimental and Clinical Medicine, AOU Careggi and University of Florence, Florence, Italy. 3. Clinical Haematology, NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK. 4. Department of Hematology, Somogy County Kaposi Mor Hospital, Kaposvar, Hungary. 5. Second Department of Internal Medicine and Cardiology Center, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary. 6. First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia. 7. Békés Megyei Pándy Kálmán Kórház, Gyula, Hungary. 8. ICON Cancer Care, South Brisbane, QLD, Australia. 9. Royal Hobart Hospital, Hobart, Australia. 10. Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic. 11. First Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 12. Department of Haematology, Christchurch Hospital, Christchurch, New Zealand. 13. CTI BioPharma Corp, Seattle, WA, USA. 14. Erasmus Medical Center, Rotterdam, Netherlands. 15. Wellcome Trust Sanger Instutite, Hinxton, UK. 16. Centre d'Investigations Cliniques, APHP, Hôpital Saint-Louis, INSERM CIC 1427, Paris, France; Paris Diderot University, Paris, France. 17. Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. METHODS: This international, multicentre, randomised, phase 3 trial (PERSIST-1) was done at 67 sites in 12 countries. Patients with higher-risk myelofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1) to receive oral pacritinib 400 mg once daily or best available therapy (BAT) excluding JAK2 inhibitors until disease progression or unacceptable toxicity. Randomisation was stratified by risk category, platelet count, and region. Treatment assignments were known to investigators, site personnel, patients, clinical monitors, and pharmacovigilance personnel. The primary endpoint was spleen volume reduction (SVR) of 35% or more from baseline to week 24 in the intention-to-treat population as assessed by blinded, centrally reviewed MRI or CT. We did safety analyses in all randomised patients who received either treatment. Here we present the final data. This trial is registered with ClinicalTrials.gov, number NCT01773187. FINDINGS:Between Jan 8, 2013, and Aug 1, 2014, 327 patients were randomly assigned to pacritinib (n=220) or BAT (n=107). Median follow-up was 23·2 months (IQR 14·8-28·7). At week 24, the primary endpoint of SVR of 35% or more was achieved by 42 (19%) patients in the pacritinib group versus five (5%) patients in the BAT group (p=0·0003). 90 patients in theBAT group crossed over to receive pacritinib at a median of 6·3 months (IQR 5·8-6·7). The most common grade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and diarrhoea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and hypotension (n=3 [3%]) in the BAT group. The most common serious adverse events that occurred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%]) with pacritinib, and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT. Deaths due to adverse events were observed in 27 (12%) patients in the pacritinib group and 14 (13%) patients in the BAT group throughout the duration of the study. INTERPRETATION:Pacritinib therapy was well tolerated and induced significant and sustained SVR and symptom reduction, even in patients with severe baseline cytopenias. Pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited. FUNDING: CTI BioPharma Corp.
RCT Entities:
BACKGROUND: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. METHODS: This international, multicentre, randomised, phase 3 trial (PERSIST-1) was done at 67 sites in 12 countries. Patients with higher-risk myelofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1) to receive oral pacritinib 400 mg once daily or best available therapy (BAT) excluding JAK2 inhibitors until disease progression or unacceptable toxicity. Randomisation was stratified by risk category, platelet count, and region. Treatment assignments were known to investigators, site personnel, patients, clinical monitors, and pharmacovigilance personnel. The primary endpoint was spleen volume reduction (SVR) of 35% or more from baseline to week 24 in the intention-to-treat population as assessed by blinded, centrally reviewed MRI or CT. We did safety analyses in all randomised patients who received either treatment. Here we present the final data. This trial is registered with ClinicalTrials.gov, number NCT01773187. FINDINGS: Between Jan 8, 2013, and Aug 1, 2014, 327 patients were randomly assigned to pacritinib (n=220) or BAT (n=107). Median follow-up was 23·2 months (IQR 14·8-28·7). At week 24, the primary endpoint of SVR of 35% or more was achieved by 42 (19%) patients in the pacritinib group versus five (5%) patients in the BAT group (p=0·0003). 90 patients in the BAT group crossed over to receive pacritinib at a median of 6·3 months (IQR 5·8-6·7). The most common grade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and diarrhoea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and hypotension (n=3 [3%]) in the BAT group. The most common serious adverse events that occurred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%]) with pacritinib, and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT. Deaths due to adverse events were observed in 27 (12%) patients in the pacritinib group and 14 (13%) patients in the BAT group throughout the duration of the study. INTERPRETATION:Pacritinib therapy was well tolerated and induced significant and sustained SVR and symptom reduction, even in patients with severe baseline cytopenias. Pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited. FUNDING: CTI BioPharma Corp.
Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: A Pardanani; R R Laborde; T L Lasho; C Finke; K Begna; A Al-Kali; W J Hogan; M R Litzow; A Leontovich; M Kowalski; A Tefferi Journal: Leukemia Date: 2013-03-05 Impact factor: 11.528
Authors: D Guschin; N Rogers; J Briscoe; B Witthuhn; D Watling; F Horn; S Pellegrini; K Yasukawa; P Heinrich; G R Stark Journal: EMBO J Date: 1995-04-03 Impact factor: 11.598
Authors: Moshe Talpaz; Ronald Paquette; Lawrence Afrin; Solomon I Hamburg; Josef T Prchal; Katarzyna Jamieson; Howard R Terebelo; Gregory L Ortega; Roger M Lyons; Ramon V Tiu; Elliott F Winton; Kavita Natrajan; Olatoyosi Odenike; David Claxton; Wei Peng; Peter O'Neill; Susan Erickson-Viitanen; Lance Leopold; Victor Sandor; Richard S Levy; Hagop M Kantarjian; Srdan Verstovsek Journal: J Hematol Oncol Date: 2013-10-29 Impact factor: 17.388
Authors: Jae Yoon Jeon; Qiuhong Zhao; Daelynn R Buelow; Mitch Phelps; Alison R Walker; Alice S Mims; Sumithira Vasu; Gregory Behbehani; James Blachly; William Blum; Rebecca B Klisovic; John C Byrd; Ramiro Garzon; Sharyn D Baker; Bhavana Bhatnagar Journal: Invest New Drugs Date: 2019-05-17 Impact factor: 3.850
Authors: Dongqing Yan; Anthony D Pomicter; Srinivas Tantravahi; Clinton C Mason; Anna V Senina; Jonathan M Ahmann; Qiang Wang; Hein Than; Ami B Patel; William L Heaton; Anna M Eiring; Phillip M Clair; Kevin C Gantz; Hannah M Redwine; Sabina I Swierczek; Brayden J Halverson; Erkan Baloglu; Sharon Shacham; Jamshid S Khorashad; Todd W Kelley; Mohamed E Salama; Rodney R Miles; Kenneth M Boucher; Josef T Prchal; Thomas O'Hare; Michael W Deininger Journal: Clin Cancer Res Date: 2018-12-18 Impact factor: 12.531
Authors: Kamal Menghrajani; Philip S Boonstra; Jessica A Mercer; Cecelia Perkins; Krisstina L Gowin; Alissa A Weber; Ruben Mesa; Jason R Gotlib; Lixia Wang; Jack W Singer; Moshe Talpaz Journal: Leuk Lymphoma Date: 2018-09-20